ES2052767T3 - Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen. - Google Patents

Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen.

Info

Publication number
ES2052767T3
ES2052767T3 ES88730187T ES88730187T ES2052767T3 ES 2052767 T3 ES2052767 T3 ES 2052767T3 ES 88730187 T ES88730187 T ES 88730187T ES 88730187 T ES88730187 T ES 88730187T ES 2052767 T3 ES2052767 T3 ES 2052767T3
Authority
ES
Spain
Prior art keywords
group
denotes
figures
image
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88730187T
Other languages
English (en)
Inventor
Julius Dr Deutsch
Jurgen Dr Conrad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2052767T3 publication Critical patent/ES2052767T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTOS DE FORMULA GENERAL I Y II,DONDE Q ES 0,1 O 2, R Y S SON LAS CIFRAS 0,1,2 Y 3, M SON LAS CIFRAS 1,2,3,4 O 5 I ES 0,1,2,3,4 O 5;RA Y RB,TIENEN EL SIGNIFICADO DADO EN LA INVENCION Y B,D Y E QUE SON IGUALES O DIFERENTES,SON EL GRUPO III,DONDE R2,K Y N TIENEN EL SIGNIFICADO EXPRESADO EN LA INVENCION. V ES A)UN RESTO DE FORMULA GENERAL (IA), SIENDO A LA FORMULA(IV),O B)UN GRUPO DE FORMULA GENERAL (IB) O (IC), CON LA CONDICION DE QUE POR MOLECULA HAY 16 A 5000 GRUPOS CH2X,ASI COMO SUS SALES CON BASES INORGANICAS Y/O ORGANICAS O AMINOACIDOS SON VALIOSOS FORMADORES DE COMPLEJOS Y COMPLEJOS PARA DIAGNOSTICO Y TERAPIA.
ES88730187T 1987-08-24 1988-08-23 Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen. Expired - Lifetime ES2052767T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873728525 DE3728525A1 (de) 1987-08-24 1987-08-24 Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel

Publications (1)

Publication Number Publication Date
ES2052767T3 true ES2052767T3 (es) 1994-07-16

Family

ID=6334556

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88730187T Expired - Lifetime ES2052767T3 (es) 1987-08-24 1988-08-23 Formadores de complejos, complejos y sales complejas, multinucleares y sustituidos, procedimientos para su preparacion, y agentes farmaceuticos que los contienen.

Country Status (6)

Country Link
EP (1) EP0305320B1 (es)
JP (1) JPH01139555A (es)
AT (1) ATE80869T1 (es)
DE (2) DE3728525A1 (es)
ES (1) ES2052767T3 (es)
GR (1) GR3005807T3 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009379A1 (en) * 1989-02-10 1990-08-23 Celltech Limited Aza-macrocycles and processes for their preparation
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
DE3922005A1 (de) * 1989-06-30 1991-01-10 Schering Ag Derivatisierte dtpa-komplexe, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
US5695739A (en) * 1989-06-30 1997-12-09 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
GB9320277D0 (en) * 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
JP3250220B2 (ja) * 1989-10-23 2002-01-28 ニコムド サルター インコーポレーテッド マルチサイト金属キレート化剤
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
US5446145A (en) * 1990-01-19 1995-08-29 Nycomed Salutar, Inc. Polychelant compounds
US5972307A (en) * 1989-10-23 1999-10-26 Nycomed Salutar, Inc. Dichelants
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5679810A (en) * 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
DE4035760A1 (de) * 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) * 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
DE4136489A1 (de) * 1991-11-06 1993-05-13 Bayer Ag Neue diethylentriamin-derivate und deren verwendung zu diagnostischen und therapeutischen zwecken
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0673655A1 (en) * 1992-03-19 1995-09-27 Daikin Industries, Limited Mri contrast medium and diagnostic method
DE4428874A1 (de) * 1994-08-08 1996-02-22 Schering Ag Dimere DTPA-Derivate und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5834456A (en) * 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
ZA976421B (en) * 1996-07-22 1998-01-22 Boehringer Mannheim Italia New bis-platinum complexes with polyamine ligands as antitumor agents.
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US6960418B2 (en) * 2003-10-23 2005-11-01 Samsung Electronics Co., Ltd. Organophotoreceptor with charge transport material with two N,N,N-trisubstituted-amino groups
DE102004026102B4 (de) * 2004-05-25 2006-08-24 Schering Ag Verfahren zur Herstellung von 1-Hydroxymethyl-1,3,5-triazapentan, Trihydrochlorid
US7189879B2 (en) 2004-05-25 2007-03-13 Schering Ag Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate

Also Published As

Publication number Publication date
GR3005807T3 (es) 1993-06-07
EP0305320A3 (en) 1989-04-12
JPH01139555A (ja) 1989-06-01
ATE80869T1 (de) 1992-10-15
EP0305320A2 (de) 1989-03-01
DE3728525A1 (de) 1989-03-16
DE3874844D1 (de) 1992-10-29
EP0305320B1 (de) 1992-09-23

Similar Documents

Publication Publication Date Title
GR3005807T3 (es)
DE59102092D1 (de) DTPA-Monoamide, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung.
NO164458C (no) Fysiologisk forenlige, paramagnetiske komplekssalter og midler for anvendelse i nmr-diagnostikk
DE59105815D1 (de) 1,4,7,10-Tetraazacyclododecan-butyltriole, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel.
NO910191D0 (no) Makrocykliske tetraazaforbindelser som inneholder en seksring, fremgangsmaate for fremstilling derav, samt farmasoeytiske midler som inneholder slike.
DE122004000051I2 (de) Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendungund Verfahren zu deren Herstellung.
ATE31537T1 (de) Peptidderivate mit polyzyklischer stickstoffstruktur, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
RU2004127136A (ru) Способ получения гамма-амидов глутамовой кислоты
DE69006116D1 (de) Peptid-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE69124132D1 (de) Tetra-aza-makrozyklen, Verfahren zu ihrer Herstellung und ihre Anwendung in NMR-Bildformung
ES2032985T3 (es) Nuevos tripeptidos de estructura policiclica nitrogenada, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DE69106276D1 (de) Säureadditionssalze einer optisch aktiven Alaninanilidverbindung und diese enthaltende, pharmazeutische Zusammensetzungen.
WO1997020841A3 (de) Neue makrobicyclische verbindungen, verfahren zu ihrer herstellung und diese makrobicyclischen verbindungen enthaltende pharmazeutische mittel
ATE120964T1 (de) Aza-makrozyklen enthaltende konjugate und verfahren zu deren herstellung.
JO1889B1 (en) New Axim derivatives of erythromycin, its preparation and use as drugs and pharmacy formulations containing it

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 305320

Country of ref document: ES